IPercept invests in AI.Fund
Funding Provisional 95% confidence first seen
Tech.eu reports that AI.Fund participated in IPercept’s $16.5M Series A funding round, which was co-led by Isogon Ventures and 2150 and included other investors such as Luminar Ventures, RunwayFBU, and J12 Venture. IPercept plans to use the funding to launch in the US, make initial local hires, and improve its AI technology for predictive maintenance of CNC machines. This matters because AI.Fund is backing an industrial AI application aimed at reducing downtime for manufacturers by turning machine motion into actionable insights.
The deal
IPercept $16.5M Series A · announced 29 Sep 2026
Investors Isogon Ventures 2150 Luminar Ventures RunwayFBU J12 Venture AI.Fund
Deal terms as reported in the coverage below.
Decision brief
- What changed
- IPercept raised a $16.5 million Series A round, with participation from AI.Fund alongside Isogon Ventures, 2150, Luminar Ventures, RunwayFBU, and J12 Venture. The company said it will use the funding to launch in the US, make initial local hires, and further improve its AI technology for predictive maintenance of CNC machines.
- Why it matters
- This signals continued investor support for industrial AI software tied to measurable operational outcomes, specifically predictive maintenance and reduced machine downtime. For business leaders in manufacturing and industrial technology, IPercept’s planned US expansion and product investment suggest a vendor in this category may become more commercially available and better resourced, which could affect partnership, procurement, or competitive positioning decisions.
- Evidence
- The event is supported by one report from Tech.eu, which states that IPercept raised a $16.5 million Series A, names AI.Fund as a participant, and describes the planned use of proceeds for US launch, hiring, and AI product improvement. The same report says the technology is already used by Airbus, Bosch, and Volvo, supporting the claim that the company has existing industrial customers.
- What remains uncertain
- The coverage does not disclose AI.Fund’s check size, ownership, or strategic role in the round, so the significance of its participation relative to other investors is unclear. It also does not verify IPercept’s revenue, deployment scale, customer contract depth, or timing and execution risk for the US expansion.
- Monitor next
- Watch for IPercept to announce named US hires, commercial launches, or additional disclosed customer deployments in the US manufacturing market.
Analytical support, not advice — assumptions and open questions stated above.